CRNO B Stock Overview
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cereno Scientific AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.70 |
| 52 Week High | SEK 9.50 |
| 52 Week Low | SEK 2.50 |
| Beta | 0.16 |
| 11 Month Change | 0% |
| 3 Month Change | -9.16% |
| 1 Year Change | 16.45% |
| 33 Year Change | 31.03% |
| 5 Year Change | 57.46% |
| Change since IPO | -8.80% |
Recent News & Updates
Shareholder Returns
| CRNO B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -8.5% | 2.1% | 0.3% |
| 1Y | 16.4% | 34.0% | 25.7% |
Return vs Industry: CRNO B underperformed the Swedish Biotechs industry which returned 29.1% over the past year.
Return vs Market: CRNO B underperformed the Swedish Market which returned 24.6% over the past year.
Price Volatility
| CRNO B volatility | |
|---|---|
| CRNO B Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: CRNO B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CRNO B's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 5 | Sten Sorensen | www.cerenoscientific.com |
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases.
Cereno Scientific AB (publ) Fundamentals Summary
| CRNO B fundamental statistics | |
|---|---|
| Market cap | SEK 1.61b |
| Earnings (TTM) | -SEK 69.48m |
| Revenue (TTM) | SEK 68.72m |
23.4x
P/S Ratio-23.1x
P/E RatioIs CRNO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNO B income statement (TTM) | |
|---|---|
| Revenue | SEK 68.72m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 68.72m |
| Other Expenses | SEK 138.20m |
| Earnings | -SEK 69.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 100.00% |
| Net Profit Margin | -101.10% |
| Debt/Equity Ratio | 17.9% |
How did CRNO B perform over the long term?
See historical performance and comparison